In 2024 2CureX has undergone a strategic reorganization, splitting into two entities: the publicly listed 2cureX AB and the privately held 2cureX A/S. This separation supports a dual-focused strategy: 2cureX AB will directly offer the CE-IVD certified and ISO13485-compliant IndiTreat® Functional Precision Oncology test to patients, while 2cureX A/S will focus on developing IndiTreat® products for decentralized use in individual hospitals. Cooperation agreements between the two entities ensure synergy, enabling both models to collectively enhance cancer care.
As part of the reorganization, Dan Honeywell, has been appointed new CEO of 2cureX AB.
Dan Honeywell, who brings more than 15 years of experience as a tech founder and business leader, will focus on accelerating commercial adoption of IndiTreat®, expanding market access, and leveraging artificial intelligence to enhance the platform’s capabilities. The company remains committed to its mission of making personalized cancer treatment selection available to patients worldwide.
Ole Thastrup, Chairman of the Board of Directors, commented: “I am delighted to welcome Dan Honeywell as CEO. His exceptional track record of transforming innovative tech companies into commercial successes and his extensive global network in oncology are invaluable assets. Dan’s leadership will be key to advancing 2cureX AB’s new commercialization strategy, delivering value to both patients and shareholders.”
Dan Honeywell, incoming CEO, stated: “I am honored to join 2cureX AB at this pivotal moment in its evolution. The company’s IndiTreat® technology represents a breakthrough in personalized cancer care, offering hope to patients by enabling truly individualized treatment decisions. Having witnessed firsthand the transformative power of healthcare innovation, I am deeply committed to accelerating 2cureX’s commercial growth while maintaining our unwavering focus on improving patient outcomes. With our dedicated team, proven technology, and clear strategic vision, we are uniquely positioned to reshape the future of precision oncology and deliver meaningful value to patients, healthcare providers, and shareholders alike.”
Read full press release